NeuroSense's PrimeC Demonstrates Efficacy in ALS, Pursues Early Approval in Canada
Key Insights
NeuroSense Therapeutics' PrimeC showed a 36% reduction in ALS (search) disease progression and a 43% improvement in survival rates in clinical trials.
The company is pursuing early commercialization approval in Canada based on Phase 2b trial results and Health Canada's Notice of Compliance with Conditions policy.
PrimeC, a novel formulation of ciprofloxacin and celecoxib, has received a key U.S. patent extending its protection to 2042.
NeuroSense Therapeutics is advancing its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (search) (ALS (search)), with recent clinical data demonstrating significant efficacy. The company is actively pursuing early commercialization approval in Canada and has been granted a key U.S. patent for the novel formulation of PrimeC, extending its intellectual property protection through 2042.
Clinical Efficacy of PrimeC in ALS
PrimeC, an extended-release oral formulation composed of a fixed-dose combination of ciprofloxacin and celecoxib, has shown promising results in clinical trials. Data from the Phase 2b PARADIGM study (NCT05357950) revealed a 36% reduction in disease progression (p=0.009) and a 43% improvement in survival rates compared to placebo. These findings underscore PrimeC's potential as a breakthrough therapy for ALS (search), a devastating neurodegenerative disease with limited treatment options.
Alon Ben-Noon, NeuroSense CEO, emphasized the innovative nature of PrimeC, stating, "PrimeC is more than a combination of two FDA-approved compounds - it's an innovative formulation that synchronizes their pharmacokinetics to unleash their full therapeutic potential. The synergy between ciprofloxacin and celecoxib is designed to maximize efficacy, pushing the boundaries of what's possible in ALS (search) treatment."
Regulatory Pathway in Canada
Based on these positive results, NeuroSense has initiated the regulatory process to seek early commercialization approval for PrimeC in Canada under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This pathway is available for medications that offer a significant improvement over current treatments for serious or life-threatening diseases, or when no alternative treatment exists.
The decision to pursue early approval in Canada aligns with recommendations from Canadian regulatory experts and reflects the urgent need for effective ALS (search) therapies. According to NeuroSense, all patients who completed the 18-month PARADIGM trial requested to continue treatment with PrimeC in an investigator-initiated study.
U.S. Patent Grant and Intellectual Property Protection
Further bolstering PrimeC's prospects, the United States Patent and Trademark Office (USPTO) has granted NeuroSense a pivotal patent (US Patent No. US 12,097,185) for the novel formulation of PrimeC. This patent, entitled "Compositions comprising Ciprofloxacin and Celecoxib," extends PrimeC's patent protection by an additional four years, until 2042. The company's intellectual property now covers the combination, formulation, and method of use of PrimeC.
Upcoming Presentations at NEALS Consortium Meeting
NeuroSense will present two abstracts focusing on PrimeC at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis (search) (NEALS) Consortium Meeting in Clearwater, Florida. Dr. Merit Cudkowicz, Chief of Neurology at Massachusetts General Hospital (MGH), will present clinical outcomes data, while Dr. Cristian Lunetta from the NEuroMuscular Omnicentre (NEMO) in Milan, Italy, will present biomarker analysis.
These presentations will further highlight the groundbreaking data from the Phase 2b PARADIGM study and NeuroSense's commitment to advancing ALS (search) research and treatment.